Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2444人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866222, encodeId=f63b18662220d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, objectType=article, longId=217212, objectId=a44c21e21243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44c21e21243, replyNumber=0, likeNumber=81, createdTime=2021-10-10, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44c21e21243, moduleTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a44c21e21243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866254, encodeId=a207186625493, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, objectType=article, longId=217877, objectId=804521e8770c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=804521e8770c, replyNumber=0, likeNumber=92, createdTime=2022-07-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=804521e8770c, moduleTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=804521e8770c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866100, encodeId=09f7186610058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量, objectType=article, longId=211990, objectId=cb0b211990bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb0b211990bb, replyNumber=0, likeNumber=102, createdTime=2022-03-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb0b211990bb, moduleTitle=Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb0b211990bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866093, encodeId=6cc4186609315, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, objectType=article, longId=211614, objectId=6cbb211614a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cbb211614a4, replyNumber=0, likeNumber=77, createdTime=2021-07-11, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cbb211614a4, moduleTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cbb211614a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866049, encodeId=5405186604979, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, objectType=article, longId=210300, objectId=c2092103002f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2092103002f, replyNumber=0, likeNumber=0, createdTime=2021-10-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2092103002f, moduleTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2092103002f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866127, encodeId=bea0186612edb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Romyelocel-L可显著降低AML患者诱导化疗期间的感染风险, objectType=article, longId=213191, objectId=526521319116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=526521319116, replyNumber=0, likeNumber=86, createdTime=2021-07-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=526521319116, moduleTitle=J Clin Oncol：Romyelocel-L可显著降低AML患者诱导化疗期间的感染风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=526521319116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866396, encodeId=d7031866396f6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, objectType=article, longId=221519, objectId=836f22151965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836f22151965, replyNumber=0, likeNumber=73, createdTime=2022-04-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836f22151965, moduleTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=836f22151965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866335, encodeId=72ed18663350f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别, objectType=article, longId=219916, objectId=49c9219916f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49c9219916f2, replyNumber=0, likeNumber=61, createdTime=2022-04-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49c9219916f2, moduleTitle=Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49c9219916f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866382, encodeId=fc8f1866382f0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：化疗对转移性前列腺癌患者的总生存期影响, objectType=article, longId=221253, objectId=76b2221253f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76b2221253f9, replyNumber=0, likeNumber=114, createdTime=2022-04-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76b2221253f9, moduleTitle=Front Oncol：化疗对转移性前列腺癌患者的总生存期影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76b2221253f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866175, encodeId=36e718661e586, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=77, createdTime=2021-08-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866236, encodeId=6a5e186623691, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=217398, objectId=e57c21e398b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57c21e398b5, replyNumber=0, likeNumber=68, createdTime=2021-10-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57c21e398b5, moduleTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57c21e398b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866506, encodeId=aa591866506a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295679, objectId=7f802956e901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f802956e901, replyNumber=0, likeNumber=61, createdTime=2022-10-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f802956e901, moduleTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f802956e901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866187, encodeId=e8d7186618e78, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, objectType=article, longId=215475, objectId=8fb22154e583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb22154e583, replyNumber=0, likeNumber=76, createdTime=2022-05-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb22154e583, moduleTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fb22154e583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866059, encodeId=5935186605947, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, objectType=article, longId=210513, objectId=1f42210513fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f42210513fc, replyNumber=0, likeNumber=0, createdTime=2021-12-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f42210513fc, moduleTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f42210513fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866371, encodeId=15ec18663e125, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：多中心数据分析DNA错配修复状态对胃癌预后影响, objectType=article, longId=221103, objectId=7e6c221103af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e6c221103af, replyNumber=0, likeNumber=82, createdTime=2022-05-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e6c221103af, moduleTitle=Front Oncol：多中心数据分析DNA错配修复状态对胃癌预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e6c221103af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866208, encodeId=2a1f186620809, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, objectType=article, longId=216567, objectId=da4821656e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da4821656e3b, replyNumber=0, likeNumber=66, createdTime=2022-04-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da4821656e3b, moduleTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da4821656e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866488, encodeId=93ae18664888b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：胃癌切除术后切缘阳性（PM）患者可推荐术后辅助化疗, objectType=article, longId=295131, objectId=7ca1295131aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ca1295131aa, replyNumber=0, likeNumber=69, createdTime=2022-07-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ca1295131aa, moduleTitle=Front Oncol：胃癌切除术后切缘阳性（PM）患者可推荐术后辅助化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ca1295131aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866427, encodeId=f9bd186642e56, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, objectType=article, longId=292663, objectId=79a729266362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79a729266362, replyNumber=0, likeNumber=73, createdTime=2022-05-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79a729266362, moduleTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79a729266362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866223, encodeId=75481866223bd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, objectType=article, longId=217213, objectId=d65521e213ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65521e213ea, replyNumber=0, likeNumber=114, createdTime=2021-11-16, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65521e213ea, moduleTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65521e213ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866455, encodeId=277618664554a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=94, createdTime=2022-09-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！

2021-10-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素

2022-07-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量

2022-03-14

hb2008ye (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果

2021-07-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！

2021-10-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Romyelocel-L可显著降低AML患者诱导化疗期间的感染风险

2021-07-28

智者为医08 (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性

2022-04-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别

2022-04-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：化疗对转移性前列腺癌患者的总生存期影响

2022-04-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2021-08-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-10-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效

2022-10-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？

2022-05-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性

2021-12-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：多中心数据分析DNA错配修复状态对胃癌预后影响

2022-05-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性

2022-04-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：胃癌切除术后切缘阳性（PM）患者可推荐术后辅助化疗

2022-07-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR

2022-05-26

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险

2021-11-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控

2022-09-07

科室
- - 订阅+
  - 更多科室
工具
服务